同源修复缺失检测在前列腺癌患者中的治疗意义（第2部分）
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
发表日期:2024 Sep 27
作者:
Anthony V Serritella, Amy Taylor, Michael C Haffner, Wassim Abida, Alan Bryce, Lawrence I Karsh, Scott T Tagawa, Przemyslaw Twardowski, Andrew J Armstrong, Joshua M Lang
DOI:
10.1038/s41391-024-00887-z
摘要
不幸的是，并非所有转移性去势抵抗性前列腺癌（mCRPC）患者都能接受延长生命的系统治疗，这凸显了优化mCRPC治疗方案的必要性。需要制定更好的指南以指导前列腺癌的遗传检测。本指南由2023-2024年召集的多学科专家小组制定，包括肿瘤科、泌尿科、放疗科、病理学、医学基因组学及基础科学代表。在第二部分中，我们强调了遗传检测如何基于近期III期临床试验和随后的PARP抑制剂获批，改善mCRPC的延长生命的治疗策略。
Abstract
Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer.In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science.In this second part, we highlight how genetic testing can lead to improved, life-prolonging mCRPC therapeutic strategies based on a review of the recent phase III trials and subsequent regulatory approvals for PARP inhibitors in mCRPC.